Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

10/28/24 5:00:00 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $AUTL alert in real time by email

LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2024 financial results and operational highlights before open of US markets on Tuesday, November 12, 2024.

Management will host a conference call and webcast at 8:30 am EDT/1:30 pm BST to discuss the company's financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus' website.

Contact:

Olivia Manser

+44 (0) 7780 471568

[email protected]

Julia Wilson

+44 (0) 7818 430877

[email protected]

Susan A. Noonan

S.A. Noonan Communications

+1-917-513-5303

[email protected]

Get the next $AUTL alert in real time by email

Date	Price Target	Rating	Analyst
11/9/2023	$10.00	Buy	Deutsche Bank
3/27/2023	$8.00	Overweight	Wells Fargo
3/17/2023	$5.00	Buy	Bryan Garnier

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Chat with this insight

Recent Analyst Ratings for
$AUTL

$AUTL
Leadership Updates

Live Leadership Updates

Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer

Autolus Therapeutics Announces Changes to its Board of Directors

Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors

$AUTL
Financials

Live finance-specific insights